Budget 2022-23

This information is accurate as at 29 March 2022.

Pharmaceutical Benefits Scheme new and amended listings

CATEGORY: Your health

The Pharmaceutical Benefits Scheme (PBS) provides subsidised access to medicines to:

* Australian residents
* overseas visitors from countries under Reciprocal Health Care Agreements.

This measure makes changes to medicines listed on the PBS. These changes are based on standard practice of recommendations to Government from the independent Pharmaceutical Benefits Advisory Committee.

**New and amended listings from 1 January 2022**

* encorafenib (Braftovi®) in combination with PBS-listed cetuximab, for patients battling colorectal cancer also known as bowel cancer.
* dapagliflozin (Forxiga®) for the treatment of symptomatic heart failure.

**New and amended listings from 1 February 2022**

* acalabrutinib (Calquence®) for the treatment of patients with mantle cell lymphoma.
* upadacitinib (Rinvoq®) to assist people with severe atopic dermatitis.

**New and amended listings from 1 March 2022**

* molnupiravir (Lagevrio®) for the treatment of adults with mild-moderate COVID-19 who have a high risk for developing severe disease, reducing the need for admission to hospital.
* methoxsalen (Uvadex®) for the treatment of chronic graft versus host disease.
* gemtuzumab ozogamicin (Mylotarg®) to help patients with acute myeloid leukaemia.
* ravulizumab (ultomiris ®) and eculizumab (Soliris®) for the treatment of paroxysmal nocturnal haemoglobinuria (PNH).

**New and amended listings from 1 April 2022**

* elexacaftor/tezacaftor/ivacaftor (Trikafta ®) for the treatment of cystic fibrosis.

**New and amended listings from 1 May 2022**

* Nintedanib (Ofev) has been included on the PBS for use in the treatment of progressive fibrosing interstitial lung disease.
* onasemnogene abeparvovec (Zolgensma®) will be listed to assist with the treatment of Spinal Muscular Atrophy.
* Sacituzumab Govitecan will be listed on the PBS for the treatment of patients with unresectable locally advanced or metastatic triple negative breast cancer.

This measure is not subject to the passage of legislation.

Who does this measure affect?

This affects Australian residents and overseas visitors from countries under Reciprocal Health Care Agreements.

**When will this start and finish?**

The new and amended PBS listings are effective on the relevant dates stated above and are ongoing.